If this is a forwarded email, subscribe now to receive future updates on this topic. |
|---|
You are subscribed to one or more CDC code set email subscription services. Subscription links are available on each of the pages below. |
|---|
Vaccine Code Set Update Publication Date: September 14, 2023
The individual filenames included in this distribution contain the publication date (20230913) Release Notes: This release includes updates for all vaccine codes and maps but does not include codes for Vaccine Information Statements (VIS). General note regarding this release: Codes with “Last Update” dates after August 24, 2023 and before September 14, 2023, reflect the changes and additions in this release. This release includes the following code set updates. New Fall 2023 COVID-19 Vaccine Codes On September 11, 2023 the FDA approved or authorized new COVID-19 vaccines for the 2023 Fall season. The following vaccines were authorized by the FDA under Emergency Use Authorization (EUA): - Pfizer: Monovalent vaccines for the Omicron XBB.1.5 virus strain for ages 6 months through 11 years
- Moderna: Monovalent vaccines for the Omicron XBB.1.5 virus strain for ages 6 months through 11 years
The following vaccines were approved by the FDA under Biologics License Application (BLA) licensure: - Pfizer: Monovalent vaccines for the Omicron XBB.1.5 virus strain for ages 12 years and older
- Moderna: Monovalent vaccines for the Omicron XBB.1.5 virus strain for ages 12 years and older
As part of FDA’s actions, the bivalent Moderna and Pfizer-BioNTech COVID-19 mRNA vaccines are no longer authorized for use in the United States. A preview codes and crosswalk table of the 2023 Fall COVID-19 codes was published ahead of FDA approvals IIS Data Code Sets | CDC. The codes referenced in that table are now incorporated and published in the full vaccine code set files. Note that while the Novavax Omicron XBB.1.5 vaccine for ages 12 years and older was not authorized by the FDA on 9/11/2023, a decision by the FDA on this vaccine is still pending. The vaccine codes for Novavax have been included in this publication, subject to FDA EUA authorization. Fall 2023 COVID-19 Vaccine Code Set Updates - Details All the CVX and NDC codes shown in the following table are new in this release. The Tradenames shown indicate if the vaccine was approved under EUA (the manufacturer name is in the tradename), or if it is approved under BLA licensure (Comirnaty and Spikevax). New CPT codes have been added for Pfizer and Moderna that are mapped to the CVX codes. However, the same CPT code is being used for the new Novavax vaccine, so that CPT code 91304 is now mapped to both prior CVX code 211 as well as to the new CVX code 313. The CDC Product table has added new entries to distinguish the EUA Fall Vaccines from prior EUA vaccine products and mapped these to the new CVX codes. The CDC Product table entries for Spikevax and Comirnaty remain the same, and mapping to the new CVX codes has been added. AMA CPT codes 91318 and 91319 contain a description error that is in process of correction by the AMA. The dose volume as published by the AMA lists the doses for these two codes as 0.2 mL – they should be listed as 0.3 mL. The CDC table below shows the correct volume, but the code set files have the volume description exactly as provided by the AMA. A future release will incorporate the corrected information once that is published by the AMA. Prior COVID-19 vaccines/codes that may be superseded by the new Fall 2023 vaccines are not addressed in this release, and may be retired at a future date.
MVX | Trade Name | CVX | CVX Term Description | CVX Short Description | UoS NDC10
UoS NDC11 | UoS Outer
Pack | UoU NDC10
UoU NDC11 | UoS
Presentation | CPT Code | CPT Description |
|---|
Pfizer (PFR) | COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | 0069-2362-10
00069-2362-10 | CARTON, 10 SINGLE-DOSE VIALS | 0069-2362-01
00069-2362-01 | VIAL, SINGLE-DOSE, 30 mcg/0.3 mL | 91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
|---|
Pfizer (PFR) | COMIRNATY (COVID-19 Vaccine, mRNA, 2023-2024 Formula) | 309 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL | 0069-2392-10
00069-2392-10 | CARTON, 10 PRE-FILLED SYRINGES | 0069-2392-01
00069-2392-01 | SYRINGE, PRE-FILLED, 30 mcg/0.3 mL | 91320 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
|---|
Pfizer (PFR) | Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) | 310 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mL | 59267-4331-2
59267-4331-02 | CARTON, 10 SINGLE-DOSE VIALS | 59267-4331-1
59267-4331-01 | VIAL, SINGLE-DOSE, 10 mcg/0.3 mL | 91319 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
|---|
Pfizer (PFR) | Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) | 308 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 3 mcg/0.3 mL dose | COVID-19, mRNA, LNP-S, PF, tris-sucrose, 3 mcg/0.3 mL | 59267-4315-2
59267-4315-02 | CARTON, 10 MULTI-DOSE VIALS | 59267-4315-1
59267-4315-01 | VIAL, MULTI-DOSE, 3 DOSES, 3mcg / 0.3 mL AFTER DILUTION | 91318 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use |
|---|
Novavax
(NVX) | Novavax COVID-19 Vaccine, Adjuvanted | 313 | SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL dose | COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mL | 80631-105-02
80631-0105-02 | CARTON, 2 MULTI-DOSE VIALS | 80631-105-01
80631-0105-01 | VIAL, MULTI-DOSE, 5 DOSES, 5 mcg/0.5 mL | 91304 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use |
|---|
Moderna
(MOD) | Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | 80777-102-95
80777-0102-95 | CARTON, 10 SINGLE-DOSE VIALS | 80777-102-04
80777-0102-04 | VIAL, SINGLE-DOSE, 50 mcg/0.5 mL | 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
|---|
Moderna
(MOD) | Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | 80777-102-96
80777-0102-96 | CARTON, 10 PRE-FILLED SYRINGES | 80777-102-01
80777-0102-01 | SYRINGE, PRE-FILLED, 50 mcg/0.5 mL | 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
|---|
Moderna
(MOD) | Spikevax | 312 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose | COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL | 80777-102-9380777-0102-93 | CARTON, 10 BLISTER-SEALED PRE-FILLED SYRINGES | 80777-102-01
80777-0102-01 | SYRINGE, PRE-FILLED, 50 mcg/0.5 mL | 91322 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use |
|---|
Moderna
(MOD) | Moderna COVID-19 Vaccine | 311 | SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL dose | COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mL | 80777-287-92
80777-0287-92 | CARTON, 10 SINGLE-DOSE VIALS | 80777-287-07
80777-0287-07 | VIAL, SINGLE-DOSE, 25 mcg/0.25 mL | 91321 | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use |
|---|
|
|---|
Centers for Disease Control and Prevention 1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348
Questions or Problems | |
|---|
|
|---|
|
